StockMarketWire.com - Hemogenyx Pharmaceuticals has chosen LakePharma as service provider for the development and manufacturing of Hemogenyx's lead product, CDX bi-specific antibodies.
The company believes that CDX bi-specific antibodies could replace traditional methods of conditioning patients for bone marrow transplants-eliminating the need for pre-transplantation chemotherapy and radiation, which can damage a patient's health-and allow more patients to benefit from the curative power of bone marrow transplants.
At 9:13am: [LON:HEMO] Hemogenyx Pharmaceuticals Plc Ord Gbp0.01 share price was 0p at 2.63p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.